Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05720767 · ClinicalTrials.gov registry record · Phase 1
HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study
A Phase 1 study, sponsored by Hutchmed.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT05720767: Completed Phase 1 study, sponsored by Hutchmed.
NCT05720767 is a Phase 1 study that has completed, run by Hutchmed. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05720767, a Phase 1 study, has completed, sponsored by Hutchmed.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
A Phase 1, Open-label, 2-Part, 2-Period Fixed-Sequence Crossover Study to Assess the Effect of Itraconazole, a CYP3A and P-glycoprotein Inhibitor, and the Effect of Rifampin, a CYP Enzyme Inducer, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers
Primary Outcome
Area under the plasma concentration-time curve from time 0 to time of the last measurable concentration
Interventions
- DRUG Rifampin
- DRUG Itraconazole
- DRUG HMPL-523
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-11-04 |
| Est. Completion | 2023-02-05 |
| Phase | Phase 1 |
What the finished NCT05720767 record still lists
NCT05720767 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 3 interventions - of which Rifampin is the first listed.
NCT05720767 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05720767 about?
NCT05720767 is a clinical study titled "HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study". A Phase 1, Open-label, 2-Part, 2-Period Fixed-Sequence Crossover Study to Assess the Effect of Itraconazole, a CYP3A and P-glycoprotein Inhibitor, and the Effect of Rifampin, a CYP Enzyme Inducer, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers
What is the current status of trial NCT05720767?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2022-11-04. Estimated completion is 2023-02-05.
What interventions are being tested in trial NCT05720767?
The interventions under investigation include: Rifampin (DRUG), Itraconazole (DRUG), HMPL-523 (DRUG).
Who is sponsoring clinical trial NCT05720767?
This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05720767's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI